Efficacy of abiraterone acetate for high-risk hormone-naïve metastatic prostate cancer: A comparison with combined androgen blockade therapy with bicalutamide and androgen deprivation therapy alone

BACKGROUND: The treatment landscape for men with metastatic hormone-naïve prostate cancer (mHNPC) has dramatically changed with the approval of next-generation anti-androgen drugs. We compared the treatment efficacy of abiraterone with that of combined androgen blockade (CAB) therapy and androgen de...

Descripción completa

Detalles Bibliográficos
Autores principales: Kanao, Kent, Takahashi, Takayuki, Umezawa, Yuta, Okabe, Takashi, Kaneko, Go, Shirotake, Suguru, Nishimoto, Koshiro, Oyama, Masafumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584391/
https://www.ncbi.nlm.nih.gov/pubmed/36264927
http://dx.doi.org/10.1371/journal.pone.0276081

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9584391/
https://www.ncbi.nlm.nih.gov/pubmed/36264927
http://dx.doi.org/10.1371/journal.pone.0276081

Ejemplares similares